Business News

SpectraCell Laboratories Now Offers Aspirin Response Testing(TM)

2008-08-04 10:39:00

SpectraCell Laboratories Now Offers Aspirin Response Testing(TM)

    HOUSTON, Aug. 4 /EMWNews/ -- SpectraCell Laboratories now offers

Aspirin Response Testing (ART(TM)). This newly available test measures a

person's response to low-dose aspirin therapy, which is routinely

prescribed to millions of Americans for cardiovascular disease prevention.

    Recent research has shown that the effects of aspirin in reducing blood

(platelet) "stickiness" will vary considerably from patient to patient. In

fact, conservative estimates suggest that aspirin resistance exists in

about 25% of the population. Since studies show that individuals who do not

respond to aspirin (in reducing platelet stickiness) are more than three

times more likely to die from heart disease than those that respond well to

aspirin, ART(TM) is vital information. Not only will ART(TM) tell a

clinician if aspirin therapy is working, but it can also help a clinician

determine the appropriate dosage of aspirin for each patient, allowing a

doctor to tailor their recommendations to the individual.

    Platelets are small blood cells that stick together to form blood clots

and control bleeding. They produce a chemical called thromboxane to attract

other platelets and increase their stickiness. Aspirin works by inhibiting

the production of thromboxane by platelets, therefore reducing their

stickiness and limiting the size of clots. ART(TM) measures the level of

thromboxane production in apparently healthy individuals.

    Specifically, ART(TM) is an enzyme-linked immunoassay (ELISA) that

measures the levels of 11-Dehydro Thromboxane B2 (11dhTxB2) in human urine.

It reflects in vivo production of thromboxane A2, which is the target of

aspirin therapy. Clinical studies such as the large HOPE (Heart Outcomes

Prevention Evaluation) study have shown that elevated levels of 11dhTxB2

correlate to increased cardiovascular risk.

    "Over one million Americans will have a heart attack this year and 40%

of those will be fatal. Many of these people are taking aspirin with the

assumption that it has the same level of efficacy on everyone," says Dr.

Fred Crawford, VP of Operations and Technical Director at SpectraCell

Laboratories. "Plus, most people assume aspirin is totally benign, which is

not always the case. For the functionally minded physician, ART(TM) is a

superb diagnostic tool for identifying asymptomatic patients whose aspirin

treatment is not working."

    There are several reasons why a patient may not respond well to

aspirin. It may be as simple as a patient taking a dose too low to

effectively inhibit thromboxane A2 production. Platelets can also be

activated by pathways that are not blocked by aspirin so other

anti-thrombotic therapies may benefit patients that are resistant to

aspirin for this reason.

    Standard platelet function tests require freshly drawn blood and must

be evaluated within four hours. However, since ART(TM) uses a random urine

sample, it is not subject to variables associated with blood sampling. In

addition, aspirin response is highly assay-specific, meaning that a patient

may not test positive for aspirin resistance with tests that stimulate

platelet aggregation in vitro via other, less specific pathways. ART(TM) is

done in vivo and specifically measures stable thromboxane metabolites. The

final results are reported in picograms of 11dhTxB2 per milligram of

creatine to standardize results to urine concentration.

    About SpectraCell Laboratories -- SpectraCell is a CLIA accredited

laboratory that services healthcare providers nationwide by providing

advanced clinical testing with the patent pending LPP(TM) (Lipoprotein

Particle Profile) and FIA(TM) (Functional Intracellular Analysis) and


    SpectraCell's LPP(TM) testing is the most advanced lipoprotein test

available. Unlike traditional cholesterol tests, SpectraCell's LPP(TM)

directly measures the number of several classes of lipoprotein particles

providing an accurate assessment of cardiovascular risk.

    SpectraCell's FIA(TM) testing is an innovative assessment of a

patient's nutritional status. Unlike traditional serum, hair and urine

tests, SpectraCell's FIA(TM) measures how an individual's white blood cells

function in specific nutritional environments. Over 30 vitamins, minerals,

amino acids and antioxidants are evaluated. With this information,

repletion programs can be implemented that take individual differences in

metabolism, age, genetics, health, prescription drug usage, absorption rate

and other factors into consideration.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website now offers Organic Lead Generation & Traffic Solutions

Blake Masterson

Freelance Writer, Journalist and Father of 5

Related Articles

Back to top button